HEARTLANDVENTURE NETWORKJoin the network
← Back to the newsroom
Deals & milestones

The O.H.I.O. Fund backs T45 Fund-II’s cardiovascular company-building model

Sourced news brief · See the publication date above and original source below.

Private funds advised by The O.H.I.O. Fund have invested in T45 Fund-II, T45 Labs and the Ohio investor announced November 3. Financial terms were not disclosed.

T45 Labs builds cardiovascular-device companies and says the investment will support portfolio development in Cleveland. Its first portfolio company, Advanced NanoTherapies, licenses drug-coated-balloon technology from Cleveland Clinic and manufactures its platform in Ohio. Other named portfolio companies include Mitria Medical, VahatiCor and NuevoSono.

This is an investment in T45 Fund-II, not a disclosed financing round for any one portfolio company and not a published fund-size announcement. Company descriptions of de-risking technologies and moving them toward clinical, regulatory or acquisition milestones do not establish patient outcomes or successful exits.

Browse Ohio startup and venture coverage and the Heartland newsroom.

Continue reading

Your story could be next.

Share what you’re building ↗